Autolus Therapeutics plc (AUTL)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 20,923 | 8,982 | - | - |
| Research and development expenses, net | 27,430 | 26,734 | 40,323 | 36,612 |
| Impairment of operating lease right-of-use assets and related property and equipment | - | - | - | 414 |
| Loss on disposal of property and equipment | - | -3 | -223 | - |
| Cost of goods sold | 24,445 | 17,951 | - | - |
| Selling, general and administrative expenses | 30,265 | 29,534 | - | - |
| General and administrative | - | - | 27,330 | 21,903 |
| Loss from operations | -61,217 | -65,240 | -67,876 | -58,929 |
| Other income, net | 135 | 129 | 54 | 1,226 |
| Interest income | 5,234 | 6,137 | 8,320 | 9,656 |
| Interest expense, net | -6,829 | 10,143 | 10,686 | 10,174 |
| Foreign exchange gains (losses), net | 1,499 | 1,181 | -11,884 | - |
| Total other income (expenses), net | 13,697 | -2,696 | -14,196 | 708 |
| Net loss before income tax | -47,520 | -67,936 | -82,072 | -58,221 |
| Income tax expenses | 397 | 2,225 | 22 | 51 |
| Net loss | -47,917 | -70,161 | -82,094 | -58,272 |
| Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of 0, 0, 0 and 0, respectively | -22 | 400 | - | - |
| Foreign currency exchange translation adjustment | 18,990 | 10,668 | 27,010 | 1,026 |
| Total other comprehensive income, net of tax | 18,968 | 11,068 | - | - |
| Total comprehensive loss | -28,949 | -59,093 | -55,084 | -57,246 |
| Basic net loss per ordinary share (in usd per share) | -0.18 | -0.26 | -0.31 | -0.22 |
| Diluted net loss per ordinary share (in usd per share) | -0.18 | -0.26 | -0.31 | -0.22 |
| Weighted-average basic ordinary shares (in shares) | 266,141,411 | 266,126,548 | 266,084,589 | 266,025,783 |
| Weighted-average diluted ordinary shares (in shares) | 266,141,411 | 266,126,548 | 266,084,589 | 266,025,783 |